You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Supernus raised the conversion rate on its 0.625% Convertible Senior Notes due 2031 from 24.0033 to 30.9355 shares per $1,000 after the September 16, 2026 special dividend, implying a conversion price of approximately $32.33 per share.
The combined company, renamed Supernus, Inc., completed its merger with Indivior Pharmaceuticals, Inc. on November 2, 2026 and borrowed $650,000,000 under a senior secured term loan facility.
Indivior Pharmaceuticals, Inc. will combine with Supernus in an all-stock merger expected to close on or about November 2, 2026. Nine-month net revenue rose 15% to $1,016 million, and it declared a $1,000 million special dividend.
Indivior said the merger is expected to close November 2, 2026, after which the combined company will operate as Supernus, Inc. and trade as “SUPN” beginning November 3, 2026.
At its October 15, 2026 special meeting, Indivior Pharmaceuticals, Inc. stockholders approved the share issuance in connection with the Merger, with 85,455,705 votes for, 5,563,744 against and 186,733 abstentions.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total SUBLOCADE net revenue | $267M | FY2026 Q3 | +21.9% |
|
|
|||
| Total SUBLOCADE net revenue (U.S. and Rest of World) | $267M | FY2026 Q3 | +21.9% |
|
|
|||
| Adj. EBITDA Margin non-GAAP | 54% | Q2 2026 | — |
| Adjusted EBITDA non-GAAP | $350M | Six Months Ended June 30, 2026 | — |
| Average share repurchase price | $37.52 | Q2 2026 | — |
|
|
|||
| Cash and investments | $249M | the 2026 quarter | — |
| common stock repurchased | $175M | the quarter ended June 30, 2026 filing | — |
| Dispense unit volume growth | 18% | Q2 2026 | — |
| Gross margin | 85% | the three months ended June 30, 2026 filing | — |
| New patient starts | 32,816 | Q2 2026 | — |
| Non-GAAP diluted earnings per share non-GAAP | $1.15 | Three Months Ended June 30, 2026 | — |
| Non-GAAP Gross Margin non-GAAP | 87% | Q2 2026 | — |
| Non-GAAP Gross Profit non-GAAP | $297M | Q2 2026 | — |
| Non-GAAP net income non-GAAP | $142M | Three Months Ended June 30, 2026 | — |
| Non-GAAP operating expenses non-GAAP | $112M | Three Months Ended June 30, 2026 | — |
| Non-GAAP research and development expenses non-GAAP | $6M | Three Months Ended June 30, 2026 | — |
| Non-GAAP selling, general and administrative expenses non-GAAP | $107M | Three Months Ended June 30, 2026 | — |
| oral buprenorphine medically assisted treatment (BMAT) average share | 14% | the three months ended June 30, 2026 filing | — |
| Other buprenorphine-based sublingual products share of net revenue | 25% | the three months ended June 30, 2026 filing | — |
| Patients prescribed SUBLOCADE since launch (U.S.) | 545,000 | As of June 30, 2026 | — |
| Share repurchase total | $175M | Q2 2026 | — |
|
|
|||
| Shares repurchased | 4,664,540 | Q2 2026 | — |
|
|
|||
| SUBLOCADE share of net revenue | 74% | the three months ended June 30, 2026 filing | — |
| SUBLOCADE share of U.S. LAI category | 76% | TTM Q2 2026 | — |
| U.S. SUBLOCADE net revenue | $238M | Q2 2026 | — |
| Year-to-date average share repurchase price | $34.73 | Year-to-date 2026 | — |
| Year-to-date share repurchase total | $300M | Year-to-date 2026 | — |
| Year-to-date shares repurchased | 8,638,693 | Year-to-date 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SUPN
this stock
Supernus, Inc.
|
$3.51B | -17.2% | +4.3% | 8.3 | 3.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.47B | +37.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$53.23B | +10.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$51.92B | +42.6% | +4.3% | 101.1 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Supernus raised the conversion rate on its 0.625% Convertible Senior Notes due 2031 from 24.0033 to 30.9355 shares per $1,000 after the September 16, 2026 special dividend, implying a conversion price of approximately $32.33 per share.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SUPN | +13.6% | -8.4% | -21.4% | -16.0% | -17.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +11.0% | -7.3% | -21.9% | -15.8% | -27.8% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
